Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib, Venetoclax and Tafasitamab (AVT) in Previously Untreated CLL/SLL
NCT07582159Phase 2Not yet recruiting
- Sponsor
- City of Hope
- Start
- Dec 2026
- Primary completion
- Apr 2029
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tafasitamab in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by City of Hope. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
tafasitamab
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT07582159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07582159.